Peregrine Pharmaceuticals Inc.'s internal review of vial coding discrepancies from a Phase II trial of bavituximab in non-small-cell lung cancer (NSCLC) showed that the errors were isolated to placebo and 1-mg/kg treatment arms, leaving the 3-mg/kg treatment arm unaffected.